[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100390753":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":26,"id":59,"slug":26,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Ohio State University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Normobaric Oxygen Therapy (40% FiO2)","EXPERIMENTAL","4 weeks of nightly normobaric oxygen therapy (40% FiO2)",[13],"Device: Normobaric Oxygen",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Condition","PLACEBO_COMPARATOR","4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)",[19],"Device: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Normobaric Oxygen","40% FiO2 for 4 weeks",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","21% FiO2 for 4 weeks",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Nicholas Breitborde, PhD","CONTACT","(614) 685-6052","nicholas.breitborde@osumc.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Harding Hospital","RECRUITING","Columbus","Ohio","43210","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-82.99879,39.96118,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":54,"phoneExt":26,"email":36},"614-685-6052",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Nicholas Breitborde","Principal Investigator","100390753",false,"NCT04368039","Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis","* Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5.\n* Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory .\n* No evidence of a pre-existing intellectual disability defined as a premorbid IQ \\>70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.\n* Ages 15-35\n* Non-smoker for past six months\n* Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale\n* The American Association for Respiratory Care notes that \"no absolute contraindications to oxygen therapy exist when indications \\[for oxygen therapy\\] are present.\"","ALL","15 Years","35 Years",{"count":68,"type":69},20,"ESTIMATED","INTERVENTIONAL",[72],"NA","Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.",[75,76,77],"Psychosis","Schizophrenia","First-episode Psychosis",[79,80,81],"psychosis","treatment","normobaric hyperoxia","2026-02-23",{"date":84,"type":85},"2026-02-25","ACTUAL",{"date":87,"type":85},"2019-12-04",{"date":89,"type":69},"2026-12-07",{"name":57,"class":6},1]